A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Oral SB1518 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) and with Thrombocytopenia
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2013
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
- Focus Registrational; Therapeutic Use
- 05 Mar 2013 Status changed from planning to discontinued.
- 01 Aug 2012 Planned initiation date changed to 1 Dec 2012.
- 06 Oct 2011 New trial record